ASP ISOTOPES INC - Asp Isotopes provides business updates

Asp Isotopes provides business updates

ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")



ASP ISOTOPES PROVIDES BUSINESS UPDATES


Washington, D.C., October 13, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP
Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology
and processes for the production of isotopes for use in multiple industries, today provided a business
development update, including a supply agreement for the largest quantity of enriched silicon-28 received
by the Company to date and a strategic acquisition of a radiopharmacy in the United States to complement
and expand the operations of PET Labs Pharmaceuticals (Pty) Ltd ("PET Labs"), the Company's South
African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of
radiopharmaceutical production.

In Summary:

    1.) The Company has entered into a supply contract with a U.S.-based customer for enriched silicon-
        28, with deliveries expected during Q1 2026. This represents the Company's largest silicon-28
        contract to date.

    2.) The Company has acquired an independent radiopharmacy located in Florida, United States. This
        acquisition is in furtherance of the Company's strategy to expand PET Labs' nuclear medicine
        business and represents PET Labs' first expansion outside South Africa. This acquisition aligns
        with PET Labs' strategy to build a vertically integrated supply chain, manufacturing and distribution
        system for the delivery of radiopharmaceutical products. This acquisition is expected to be accretive
        to 2026 revenues, EBITDA and EPS.

Enriched Silicon-28: Enabling the Quantum Future

In September 2025, the Company entered into a supply contract with a U.S.-based customer for enriched
silicon-28, with deliveries expected during Q1 2026. This represents the Company's largest silicon-28
contract to date.

Isotopically pure silicon-28 is a key material in the development of solid-state quantum computing and
advanced semiconductor architectures. By removing the nuclear spin noise present in natural silicon,
enriched silicon-28 provides a pristine environment for qubits, dramatically improving coherence times and
overall device performance. This unique material advantage is critical for building scalable, fault-tolerant
quantum processors that can operate reliably at industrial scale.
As global investment in quantum computing and advanced electronics accelerates, demand for high-purity
silicon-28 continues to grow. The ability to supply this material at commercial scale marks an important step
toward establishing a robust and diversified supply chain for the next generation of computing technologies.

Viktor Petkov, Chief Commercial Officer of ASP Isotopes, commented: "This significant customer order for
silicon-28 underscores how our Electronic Gases strategy is gaining real traction across multiple end
markets. Enriched silicon is emerging as a cornerstone material not only for quantum computing but also
for high-precision semiconductor and photonics applications. Our goal is to become the world's most
reliable supplier of enriched silane and other isotopically pure gases — a foundation for the technologies
driving the next industrial revolution. The scale and sophistication of demand we are seeing confirm that
this is rapidly becoming one of the most dynamic sectors in advanced materials."

PET Labs – Expanding Globally in a Growing RadioPharmacy Market

In October 2025, the Company acquired an independent radiopharmacy in Florida, United States, to
complement and expand the operations of PET Labs (the Company's South African radiopharmaceutical
operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production).
The Florida radiopharmacy currently offers only SPECT services and with PET Labs' expertise, the
Company expects to start offering PET services from 2027 onwards. These additional services are
expected to grow revenues and profits in future years. This small acquisition is expected to be accretive to
revenues, EBITDA and EPS during 2026.

The Company has a strategy to further expand PET Labs' business and activities in the United States and
other jurisdictions to meet the increasing demand for radiodiagnostics and radiotherapeutics. PET Labs
has recently signed an additional non-binding term sheet for an additional acquisition in the United States
and is in discussions with multiple independent radiopharmacies in different jurisdictions for acquisition
opportunities. PET Labs aims to build a radiopharmacy network that is vertically integrated with the
capabilities to produce the stable isotopes that are subsequently used for the production of radioisotopes.
The Company believes that this will provide PET Labs with a significant competitive advantage over its
competition.

Dr Gerdus Kemp, CEO of PET Labs commented "This acquisition marks the first important step in the
planned expansion of PET Labs outside South Africa. Over the next several years we expect to grow PET
Labs with both brownfield expansions such as this, as well as greenfield expansions, with the goal to
ultimately turn PET Labs into a global leader in the production of radioisotopes to treat many forms of
oncology."

PET Labs looks forward to providing access to investors at its South African facilities during the Company's
upcoming Investor Access Event (November 12- 13, 2025). During the event, PET Labs will also provide
greater detail on its growth strategy, as well as providing further information on its four biotechnology assets
that have been developed from first principles in South Africa that are expected to enter Phase I human
clinical trials in South Africa during 2026 for various difficult to treat oncology indications.

Inducement Award

In connection with commencing employment with Quantum Leap Energy LLC, a new non-executive
employee of ASP Isotopes Inc. was granted an award of restricted stock covering an aggregate of 30,000
shares of the Company's common stock. The shares of restricted stock will vest, based on continued
service to ASP Isotopes Inc. or Quantum Leap Energy LLC, in eight equal semi-annual installments over
a four-year period. The restricted stock award was approved by the Board of Directors and was granted
under the Company's 2024 Inducement Equity Incentive Plan as an employment inducement award in
accordance with Nasdaq Listing Rule 5635(c)(4).

About ASP Isotopes Inc.

ASP Isotopes Inc. is an advanced materials company dedicated to developing technology and processes
to produce isotopes in multiple industries. The Company employs proprietary technology, the Aerodynamic
Separation Process ("ASP technology"), for the production of all isotopes. The Company's initial focus is
on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
The Company also plans to enrich isotopes for the nuclear energy sector. The Company has isotope
enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a
low atomic mass (light isotopes).

There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare
applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP
Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass
molecules. For more information, please visit www.aspisotopes.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions
of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements relating
to the plans to deploy technologies to the enrichment of uranium. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, and other future conditions. Forward-looking
statements can be identified by words such as "believes," "plans," "anticipates," "expects," "estimates,"
"projects," "will," "may," "might," and words of a similar nature. Examples of forward-looking statements
include, among others but are not limited to, statements we make regarding expected operating results,
such as future revenues and prospects from the potential commercialization of isotopes, future performance
under contracts, and our strategies for product development, engaging with potential customers, market
position, and financial results. Because forward-looking statements relate to the future, they are subject to
inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are
outside our control. Our actual results, financial condition, and events may differ materially from those
indicated in the forward-looking statements based upon a number of factors. Forward-looking statements
are not a guarantee of future performance or developments. You are strongly cautioned that reliance on
any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you
should not rely on any of these forward-looking statements.

There are many important factors that could cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements, including, but not limited to: the outcomes
of various strategies and projects undertaken by the Company; the potential impact of laws or government
regulations or policies in South Africa, the United Kingdom or elsewhere; our future capital requirements
and sources and uses of cash; our ability to obtain funding for our operations and future growth; our reliance
on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment
plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our
ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of
any current and future commercial arrangements; our ability to complete certain transactions and realize
anticipated benefits from acquisitions; contracts, dependence on our Intellectual Property (IP) rights, certain
IP rights of third parties; the competitive nature of our industry; risks related to: (i) the implementation of the
scheme of arrangement for the proposed Renergen acquisition in the anticipated timeframe or at all, (ii) the
satisfaction of the scheme conditions, (iii) the failure to obtain necessary regulatory approvals and third
party consents, (iv) the ability to realize the anticipated benefits of the proposed acquisition of Renergen,
(v) the ability to successfully integrate the businesses; (vi) disruption from the proposed acquisition of
Renergen making it more difficult to maintain business and operational relationships, (vii) the negative
effects of the consummation of the proposed acquisition of Renergen on the market price of Renergen's or
ASPI's securities, (viii) significant transaction costs and unknown liabilities, and (ix) litigation or regulatory
actions related to the proposed acquisition of Renergen; and the factors disclosed under the heading "Risk
Factors" in the company's Annual Report on Form 10-K, quarterly reports on Form 10-Q and any other
filings made with the SEC from time to time, which are available via the SEC's website at www.sec.gov.
Any forward-looking statement made by us in this press release is based only on information currently
available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new information, future developments or
otherwise. All forward-looking statements herein are qualified by reference to the cautionary statements set
forth herein and should not be relied upon.

Contacts

Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043


13 October 2025

Sponsor
Valeo Capital Proprietary Limited

Date: 13-10-2025 02:16:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.